{"id":54540,"date":"2026-04-28T21:54:00","date_gmt":"2026-04-28T14:54:00","guid":{"rendered":"https:\/\/thaipropertynews.com\/feeds\/?p=54540"},"modified":"2026-04-28T21:54:00","modified_gmt":"2026-04-28T14:54:00","slug":"fosun-pharma-announces-q1-2026-results-net-profit-attributable-to-shareholders-after-deducting-non-recurring-gains-and-losses-increased-by-21-96-yoy-with-strong-pipeline-execution","status":"publish","type":"post","link":"https:\/\/thaipropertynews.com\/feeds\/?p=54540","title":{"rendered":"Fosun Pharma Announces Q1 2026 Results: Net Profit Attributable to Shareholders After Deducting Non-Recurring Gains and Losses Increased by 21.96% YoY, With Strong Pipeline Execution"},"content":{"rendered":"

SHANGHAI<\/span>, April 28, 2026<\/span> \/PRNewswire\/ — On 28 April, Fosun Pharma<\/b>\u00a0(“the Company”, stock code: 600196.SH; 02196.HK) announced its results for the first quarter of 2026 (the reporting period). During the reporting period, the Company achieved a total revenue of RMB 10,073 million, representing a year-on-year increase of 6.93%. Regarding R&D investment, the Company firmly implemented its innovation transformation strategy. During the reporting period, the R&D expenditure increased to RMB 897 million, increased by 1.59% YoY. While increasing the R&D intensity, the Company maintained a positive growth trend in profit. Net profit attributable to\u00a0shareholders of the list company after deducting extraordinary gain or loss was RMB 501 million, up 21.96% year-on-year. Net profit attributable to shareholders of the listed company was RMB 871 million, increased by 13.87% YoY. Net cash flows generated from operating activities was RMB 1,149 million, up 8.8% YoY.<\/p>\n

In the first quarter of 2026, guided by the strategy of\u00a0“<\/b>Innovation Driven, Deep Globalization, and AI Embracement”, Fosun Pharma firmly continued to advance its\u00a0innovation transformation, promoted the deep synergy between\u00a0innovation and R&D and\u00a0global operations, and further enhanced the foundation for\u00a0high-quality development. Driven by the continuous increase in R&D investment, the Company’s transformation of innovative achievements continues to materialize. During the reporting period, the NDA for 4 Innovative Drugs were accepted by the NMPA\u00a0or the\u00a0U.S. FDA, and 14 clinical trials for Innovative Drugs (calculated by approval) were approved by domestic and overseas regulatory authorities, covering core therapeutic areas such as\u00a0oncology. In the\u00a0Pharma R&D Annual Review 2026<\/i>\u00a0white paper released by the world-known consulting firm\u00a0Citeline<\/i>, Fosun Pharma ranked among the\u00a0global top 20, gained international professional recognition for its innovative R&D strength and pipeline quality.<\/p>\n

Deepening Core Technology Platforms to Consolidate Advantages in Oncology and Other Fields<\/b><\/p>\n

Fosun Pharma has established an\u00a0open-ended R&D system\u00a0that combines\u00a0in-house R&D, co-development, licensing, fund incubation, and industrial investment, also focused on strengthening core technology platforms such as\u00a0antibodies\/ADC, small molecules, and cell therapy, continuously consolidating its\u00a0innovation moat\u00a0in core therapeutic areas including oncology.<\/p>\n

In the field of antibody\/ADC technology platform,\u00a0Shanghai Henlius, a subsidiary of Fosun Pharma, has steadily advanced the approvals and clinical progress of several self-developed biological drugs. Notably,\u00a0denosumab injection (HLX14) secured approval in\u00a0Canada\u00a0in March 2026, covering all indications of the reference product approved locally, achieving a global commercialization breakthrough in areas such as\u00a0osteoporosis, bone metastasis from tumors, and giant cell tumor of bone. The NDA for\u00a0bevacizumab injection (HLX04)\u00a0was accepted in the\u00a0U.S., marking a new milestone in the Company’s international registration capabilities for\u00a0biosimilars.\u00a0HLX43, an antibody-drug conjugate targeting PD-L1, is expected to create synergy with\u00a0HLX07\u00a0or\u00a0serplulimab injection for the treatment of advanced colorectal cancer and other solid tumors.\u00a0HLX3901, a\u00a0tetraspecific antibody of DLL3\u00d7DLL3\u00d7CD3\u00d7CD28, received approval for clinical trial, demonstrating significant potential in\u00a0refractory solid tumors\u00a0through multi-target synergistic activation of immune cells.<\/p>\n

In the field of small molecule innovative drug platform,\u00a0in January 2026, the NDA for\u00a0foritinib succinate capsules (SAF-189), Fosun Pharma’s Class 1 innovative drug, was accepted by the NMPA, intended for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC), expected to provide a new option for precision treatment of lung cancer. In February 2026, the NDA for the self-developed\u00a0MEK 1\/2 inhibitor luvometinib tablets (Trade name in Chinese mainland: Fu Mai Ning)<\/sup>\u00a0for adult patients with neurofibromas type 1 (NF1) with symptomatic, inoperable plexiform neurofibromas (PN) have been accepted and granted in the priority review\u00a0by the NMPA. This marks a critical step toward full-age coverage following its approval for pediatric and adolescent NF1 patients in May 2025, also brings new hope to a large number of adult NF1 patients in China who lack effective drug treatments. Additionally, the NDA for\u00a0methoxyetomidate hydrochloride injection (ET-26), a Class 1 innovative drug self-developed by the subsidiary\u00a0Avanc Pharma\u00a0for anesthesia induction and short-term surgical anesthesia, was also accepted.<\/p>\n

In the field of prospective layout of early-stage pipeline, several new molecules have been approved for the clinical trials: FXB0871, a PD-1-targeted IL-2 fusion protein,\u00a0was approved for clinical trials in locally advanced or metastatic solid tumors. Based on the\u00a0ATTENUKINE\u2122\u00a0platform, FXB0871 is expected to achieve high efficacy and low toxicity. FXS0683, a next-generation\u00a0Bcl-2 inhibitor, was approved for Phase I clinical trials in\u00a0hematological malignancies. Innovative molecule including HLX97\u00a0(a KAT6A\/B small molecule inhibitor) and\u00a0HLX3901 (tetra specific antibody of DLL3\u00d7DLL3\u00d7CD3\u00d7CD28)\u00a0were approved for clinical trials, widely covering refractory solid tumors such as\u00a0breast cancer\u00a0and\u00a0small cell lung cancer. Meanwhile, HLX22\u00a0(anti-HER2 monoclonal antibody)\u00a0entered phase II clinical trials for the first-line treatment of\u00a0HER2-positive recurrent or metastatic breast cancer in combination with\u00a0HLX87. HLX43 (PD-L1 ADC) in combination with HLX07 or serplulimab injection, and HLX701 (CD47 fusion protein), among others, have entered Phase I clinical trials, further enhancing the Company’s layout in the fields of tumor immunology and targeted therapy.<\/p>\n

Expanding Global Commercialization Network and Enhancing Academic Influence<\/b><\/p>\n

During the reporting period, Fosun Pharma’s\u00a0global registration and commercialization network\u00a0continued to expand. The overseas registration of products like denosumab and bevacizumab progressed steadily. The Company reached deep collaborations with global partners such as\u00a0Eisai\u00a0and\u00a0Abbott\u00a0to accelerate the market coverage of innovative products in\u00a0Japan, Asia-Pacific, Middle East, Africa, and Eastern Europe.<\/p>\n

In the academic field, several innovation achievements were presented at top international conferences such as\u00a0AACR and\u00a0ASCO. The Phase III study data of\u00a0luvometinib tablets\u00a0for adult patients with neurofibromas type 1 (NF1) with symptomatic, inoperable plexiform neurofibromas (PN) was selected for a\u00a0rapid oral abstract session\u00a0at\u00a02026 ASCO, the study results will be released for the first time during the meeting. At the\u00a02026 AACR Annual Meeting, Shanghai Henlius, a Fosun Pharma’s subsidiary, presented preclinical data for the novel\u00a0trispecific T-cell engager HLX3902\u00a0and the\u00a0tetraspecific antibody HLX3901, demonstrating\u00a0best-in-class\u00a0treatment potential, building a solid foundation for the future clinical development.<\/p>\n

AI Embracement: Driving Digital Transformation via FoSTRAID<\/b><\/p>\n

Fosun Pharma continues to deepen its digitalization and AI strategic layout, and systematically advances the platformisation, engineering and scaled implementation of AI capabilities focusing on core aspects such as new drug R&D, clinical research, products and services, and operation management. On this basis, the fully AI- embracing strategy centered on FoSTRAID (Fosun Pharma Strategic Transformation via AI & Data science) was further defined and steadily advanced. By integrating resources, a digital-intelligence architecture that promotes synergistic development across “foundation \u2014 platform \u2014 data \u2014 agent \u2014 scenario \u2014 mechanism” has been established.<\/p>\n

The self-developed\u00a0PharmAID\u00ae<\/sup> Pharmaceutical Intelligence Platform deeply applies\u00a0large language models, fine-tuned with professional medical corpora and R&D data. It integrates full-cycle of decision-making tools including\u00a0competitor analysis, clinical competitive performance evaluation, NDA approval prediction, and peak sales estimation, comprehensively applied in key scenarios such as target discovery, molecular optimization, clinical writing, intelligence retrieval, and literature interpretation, providing systematic and data-driven support for drug R&D decision-making.<\/p>\n

Looking ahead, Fosun Pharma will continue to adhere to the dual drivers of\u00a0innovation and globalization,\u00a0deepen its core technology platforms, promote the implementation of AI strategy and accelerate the transformation of its pipeline and global market access. The Company remains committed to providing high-quality healthcare products and services to patients worldwide, striving to become a\u00a0leading global healthcare innovation integrator.<\/p>\n

– END –<\/p>\n

About Fosun Pharma<\/u><\/b><\/p>\n

Founded in 1994, Fosun Pharma (stock code: 600196.SH; 02196.HK) is an innovation-driven global pharmaceutical and healthcare group. With the mission of Better Health for Families Worldwide, we focus on developing innovative medicines, medical technologies and diagnostics as well as delivering healthcare services. Through our business partner Sinopharm Group, we have also established pharmaceutical distribution network, built a comprehensive pharmaceutical and healthcare ecosystem.<\/p>\n

Fosun Pharma is dedicated to innovation and globalization. The company has established a global R&D innovation system targeting at unmet medical needs. Our strategic focus is on key therapeutic areas including oncology, immunology and inflammation, neurodegenerative diseases, and selected cardiometabolic diseases and rare diseases. This approach enables the development of high valued competitive pipelines and comprehensive healthcare solutions. Meanwhile, Fosun Pharma has consolidated its core technical platforms including but not limited to antibodies and antibody-drug conjugates (ADC), small molecules and cell therapy. Additionally, we also actively advance cutting-edge therapeutic modalities such as radiopharmaceuticals and small nucleic acids. These efforts have strengthened our early-stage innovative portfolios and accelerated the transformation of scientific discoveries to drug development. Our innovative products are now available in more than 90 countries and regions worldwide, including major markets across China, the United States, Europe, Africa, India and Southeast Asia.<\/p>\n

Looking ahead, guided by the strategy of “Innovation Driven, Deep Globalization, and AI Embracement”, Fosun Pharma remains committed to its core values: Care for life, Continuous innovation, Pursuit of excellence and Sustainable partnership. We strive to become a leading global healthcare innovation integrator, ensuring that the benefits of medical innovation reach more patients worldwide, and contribute to safeguarding human health.<\/p>\n

For more information about the Group, please visit the company website: https:\/\/www.fosunpharma.com\/en\/<\/a><\/p>","protected":false},"excerpt":{"rendered":"

<\/p>\n

SHANGHAI<\/span>, April 28, 2026<\/span> \/PRNewswire\/ — On 28 April, Fosun Pharma<\/b>\u00a0(“the Company”, stock code: 600196.SH; 02196.HK) announced its results for the first quarter of 2026 (the reporting period). During the reporting period, the Company achieved a total revenue of RMB 10,073 million, representing a year-on-year increase of 6.93%. Regarding R&D investment, the Company firmly implemented its innovation transformation strategy. During the reporting period, the R&D expenditure increased to RMB 897 million, increased by 1.59% YoY. While increasing the R&D intensity, the Company maintained a positive growth trend in profit. Net profit attributable to\u00a0shareholders of the list company after deducting extraordinary gain or loss was RMB 501 million, up 21.96% year-on-year. Net profit attributable to shareholders of the listed company was RMB 871 million, increased by 13.87% YoY. Net cash flows generated from operating activities was RMB 1,149 million, up 8.8% YoY.<\/p>\n

In the first quarter of 2026, guided by the strategy of\u00a0“<\/b>Innovation Driven, Deep Globalization, and AI Embracement”, Fosun Pharma firmly continued to advance its\u00a0innovation transformation, promoted the deep synergy between\u00a0innovation and R&D and\u00a0global operations, and further enhanced the foundation for\u00a0high-quality development. Driven by the continuous increase in R&D investment, the Company’s transformation of innovative achievements continues to materialize. During the reporting period, the NDA for 4 Innovative Drugs were accepted by the NMPA\u00a0or the\u00a0U.S. FDA, and 14 clinical trials for Innovative Drugs (calculated by approval) were approved by domestic and overseas regulatory authorities, covering core therapeutic areas such as\u00a0oncology. In the\u00a0Pharma R&D Annual Review 2026<\/i>\u00a0white paper released by the world-known consulting firm\u00a0Citeline<\/i>, Fosun Pharma ranked among the\u00a0global top 20, gained international professional recognition for its innovative R&D strength and pipeline quality.<\/p>\n

Deepening Core Technology Platforms to Consolidate Advantages in Oncology and Other Fields<\/b><\/p>\n

Fosun Pharma has established an\u00a0open-ended R&D system\u00a0that combines\u00a0in-house R&D, co-development, licensing, fund incubation, and industrial investment, also focused on strengthening core technology platforms such as\u00a0antibodies\/ADC, small molecules, and cell therapy, continuously consolidating its\u00a0innovation moat\u00a0in core therapeutic areas including oncology.<\/p>\n

In the field of antibody\/ADC technology platform,\u00a0Shanghai Henlius, a subsidiary of Fosun Pharma, has steadily advanced the approvals and clinical progress of several self-developed biological drugs. Notably,\u00a0denosumab injection (HLX14) secured approval in\u00a0Canada\u00a0in March 2026, covering all indications of the reference product approved locally, achieving a global commercialization breakthrough in areas such as\u00a0osteoporosis, bone metastasis from tumors, and giant cell tumor of bone. The NDA for\u00a0bevacizumab injection (HLX04)\u00a0was accepted in the\u00a0U.S., marking a new milestone in the Company’s international registration capabilities for\u00a0biosimilars.\u00a0HLX43, an antibody-drug conjugate targeting PD-L1, is expected to create synergy with\u00a0HLX07\u00a0or\u00a0serplulimab injection for the treatment of advanced colorectal cancer and other solid tumors.\u00a0HLX3901, a\u00a0tetraspecific antibody of DLL3\u00d7DLL3\u00d7CD3\u00d7CD28, received approval for clinical trial, demonstrating significant potential in\u00a0refractory solid tumors\u00a0through multi-target synergistic activation of immune cells.<\/p>\n

In the field of small molecule innovative drug platform,\u00a0in January 2026, the NDA for\u00a0foritinib succinate capsules (SAF-189), Fosun Pharma’s Class 1 innovative drug, was accepted by the NMPA, intended for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC), expected to provide a new option for precision treatment of lung cancer. In February 2026, the NDA for the self-developed\u00a0MEK 1\/2 inhibitor luvometinib tablets (Trade name in Chinese mainland: Fu Mai Ning)<\/sup>\u00a0for adult patients with neurofibromas type 1 (NF1) with symptomatic, inoperable plexiform neurofibromas (PN) have been accepted and granted in the priority review\u00a0by the NMPA. This marks a critical step toward full-age coverage following its approval for pediatric and adolescent NF1 patients in May 2025, also brings new hope to a large number of adult NF1 patients in China who lack effective drug treatments. Additionally, the NDA for\u00a0methoxyetomidate hydrochloride injection (ET-26), a Class 1 innovative drug self-developed by the subsidiary\u00a0Avanc Pharma\u00a0for anesthesia induction and short-term surgical anesthesia, was also accepted.<\/p>\n

In the field of prospective layout of early-stage pipeline, several new molecules have been approved for the clinical trials: FXB0871, a PD-1-targeted IL-2 fusion protein,\u00a0was approved for clinical trials in locally advanced or metastatic solid tumors. Based on the\u00a0ATTENUKINE\u2122\u00a0platform, FXB0871 is expected to achieve high efficacy and low toxicity. FXS0683, a next-generation\u00a0Bcl-2 inhibitor, was approved for Phase I clinical trials in\u00a0hematological malignancies. Innovative molecule including HLX97\u00a0(a KAT6A\/B small molecule inhibitor) and\u00a0HLX3901 (tetra specific antibody of DLL3\u00d7DLL3\u00d7CD3\u00d7CD28)\u00a0were approved for clinical trials, widely covering refractory solid tumors such as\u00a0breast cancer\u00a0and\u00a0small cell lung cancer. Meanwhile, HLX22\u00a0(anti-HER2 monoclonal antibody)\u00a0entered phase II clinical trials for the first-line treatment of\u00a0HER2-positive recurrent or metastatic breast cancer in combination with\u00a0HLX87. HLX43 (PD-L1 ADC) in combination with HLX07 or serplulimab injection, and HLX701 (CD47 fusion protein), among others, have entered Phase I clinical trials, further enhancing the Company’s layout in the fields of tumor immunology and targeted therapy.<\/p>\n

Expanding Global Commercialization Network and Enhancing Academic Influence<\/b><\/p>\n

During the reporting period, Fosun Pharma’s\u00a0global registration and commercialization network\u00a0continued to expand. The overseas registration of products like denosumab and bevacizumab progressed steadily. The Company reached deep collaborations with global partners such as\u00a0Eisai\u00a0and\u00a0Abbott\u00a0to accelerate the market coverage of innovative products in\u00a0Japan, Asia-Pacific, Middle East, Africa, and Eastern Europe.<\/p>\n

In the academic field, several innovation achievements were presented at top international conferences such as\u00a0AACR and\u00a0ASCO. The Phase III study data of\u00a0luvometinib tablets\u00a0for adult patients with neurofibromas type 1 (NF1) with symptomatic, inoperable plexiform neurofibromas (PN) was selected for a\u00a0rapid oral abstract session\u00a0at\u00a02026 ASCO, the study results will be released for the first time during the meeting. At the\u00a02026 AACR Annual Meeting, Shanghai Henlius, a Fosun Pharma’s subsidiary, presented preclinical data for the novel\u00a0trispecific T-cell engager HLX3902\u00a0and the\u00a0tetraspecific antibody HLX3901, demonstrating\u00a0best-in-class\u00a0treatment potential, building a solid foundation for the future clinical development.<\/p>\n

AI Embracement: Driving Digital Transformation via FoSTRAID<\/b><\/p>\n

Fosun Pharma continues to deepen its digitalization and AI strategic layout, and systematically advances the platformisation, engineering and scaled implementation of AI capabilities focusing on core aspects such as new drug R&D, clinical research, products and services, and operation management. On this basis, the fully AI- embracing strategy centered on FoSTRAID (Fosun Pharma Strategic Transformation via AI & Data science) was further defined and steadily advanced. By integrating resources, a digital-intelligence architecture that promotes synergistic development across “foundation \u2014 platform \u2014 data \u2014 agent \u2014 scenario \u2014 mechanism” has been established.<\/p>\n

The self-developed\u00a0PharmAID\u00ae<\/sup> Pharmaceutical Intelligence Platform deeply applies\u00a0large language models, fine-tuned with professional medical corpora and R&D data. It integrates full-cycle of decision-making tools including\u00a0competitor analysis, clinical competitive performance evaluation, NDA approval prediction, and peak sales estimation, comprehensively applied in key scenarios such as target discovery, molecular optimization, clinical writing, intelligence retrieval, and literature interpretation, providing systematic and data-driven support for drug R&D decision-making.<\/p>\n

Looking ahead, Fosun Pharma will continue to adhere to the dual drivers of\u00a0innovation and globalization,\u00a0deepen its core technology platforms, promote the implementation of AI strategy and accelerate the transformation of its pipeline and global market access. The Company remains committed to providing high-quality healthcare products and services to patients worldwide, striving to become a\u00a0leading global healthcare innovation integrator.<\/p>\n

– END –<\/p>\n

About Fosun Pharma<\/u><\/b><\/p>\n

Founded in 1994, Fosun Pharma (stock code: 600196.SH; 02196.HK) is an innovation-driven global pharmaceutical and healthcare group. With the mission of Better Health for Families Worldwide, we focus on developing innovative medicines, medical technologies and diagnostics as well as delivering healthcare services. Through our business partner Sinopharm Group, we have also established pharmaceutical distribution network, built a comprehensive pharmaceutical and healthcare ecosystem.<\/p>\n

Fosun Pharma is dedicated to innovation and globalization. The company has established a global R&D innovation system targeting at unmet medical needs. Our strategic focus is on key therapeutic areas including oncology, immunology and inflammation, neurodegenerative diseases, and selected cardiometabolic diseases and rare diseases. This approach enables the development of high valued competitive pipelines and comprehensive healthcare solutions. Meanwhile, Fosun Pharma has consolidated its core technical platforms including but not limited to antibodies and antibody-drug conjugates (ADC), small molecules and cell therapy. Additionally, we also actively advance cutting-edge therapeutic modalities such as radiopharmaceuticals and small nucleic acids. These efforts have strengthened our early-stage innovative portfolios and accelerated the transformation of scientific discoveries to drug development. Our innovative products are now available in more than 90 countries and regions worldwide, including major markets across China, the United States, Europe, Africa, India and Southeast Asia.<\/p>\n

Looking ahead, guided by the strategy of “Innovation Driven, Deep Globalization, and AI Embracement”, Fosun Pharma remains committed to its core values: Care for life, Continuous innovation, Pursuit of excellence and Sustainable partnership. We strive to become a leading global healthcare innovation integrator, ensuring that the benefits of medical innovation reach more patients worldwide, and contribute to safeguarding human health.<\/p>\n

For more information about the Group, please visit the company website: https:\/\/www.fosunpharma.com\/en\/<\/a><\/p>\n

<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":[],"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[5,7],"tags":[],"class_list":["post-54540","post","type-post","status-publish","format-standard","hentry","category-cision-pr-newswire","category-cision-pr-newswire-en"],"_links":{"self":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/54540","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=54540"}],"version-history":[{"count":0,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/54540\/revisions"}],"wp:attachment":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=54540"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=54540"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=54540"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}